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the evolution of castrate resistant prostate cancer (CRPC) allows for
deep insight into the pathways involved in promotion, progression
and metastases. Characterisation of aberrations in the androgen
receptor pathway, DNA repair pathways, cell cycle pathways, PI3
kinase pathways and WNT pathway will allow integration of this
knowledge to drive therapeutic strategies.
In 2013, Baca et al in Cell1 sequenced genome of 55 primary
prostate adenocarcinomas and 2 neuroendocrine prostate metas-
tases with matched normal tissue and identiﬁed signiﬁcant DNA
aberrations namely; rearrangements, copy number alterations and
point mutations. There was an average of 33 non-silent exonic
mutations per primary tumour, and from this preliminary data they
were able to characterise inter-related sets of rearrangements and
deletions that gave deep insights into the pathogenesis of prostate
cancer. There are multiple fusion genes that occur within this dis-
ease and analyses have identiﬁed a process called chromoplexy to
encapsulate the complex process of gene rearrangements that
occur here. The most well-characterised of these gene fusion pro-
teins involve the TMPRSS2:ERG families. Identiﬁed by Tomlins et al
in 2005 in Science,2 the gene fusion juxtaposes transmembrane
protease serine 2 (TMPRSS2) and the V-ETS avian erythroblastosis
virus E26 oncogene-homolog (ERG), bringing the androgen sensi-
tive promoter of TMPRSS2 to the coding region of the transcription
factor ERG, the latter of which is involved in induction of epithelial
mesenchymal transition and increases in cell motility. ETS fusion
negative tumours harbour mutations in other genes such as SPOP,
CHD1, and MAP3K7 as well as over expression of SPINK1.* Corresponding author: Paul Mainwaring (pmainwaring@iconcancercare.com.au).
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p2287-8882 e2287-903XIn 2012, the Cancer Genome Anatomy Project3 sequenced 50
heavily pre-treated metastatic castrate resistant prostate cancers
also demonstrating extensive ETS fusion genes and in particular
identiﬁed ERG ‘partners’ within the androgen receptor pathway,
which are driven by this novel fusion protein family. The most
common aberrations identiﬁed were ampliﬁcation of the androgen
receptor pathway, loss of PTEN within the PI3 kinase pathway,
mutations in P53, loss of retinoblastoma protein as well as ZFHX3, a
transcription factor associated with c-MYC/MYB pathway. Further
more changes in the epigenetic programming genes such as MLL2
and MLL4 rounded out our understanding of castrate resistant
progression at that time. Indeed in the Robinson Cell paper of 2015,
approximately 90% of metastatic castrate resistant prostate cancers
harboured clinically actionable molecular aberrations, and of note,
almost one quarter of them harboured deﬁciencies in DNA repair
pathways that may be amenable to emerging therapies in this area
such as PARP inhibitors.
Synthesising this data, it appears that there are indexed
genomic alterations that occur early on in the primary tumour
involving these crucial pathways, i.e. androgen receptor, PI3 kinase,
WNT, DNA repair and the TP53 gene and over time the clonal se-
lection of disease that has escaped prior to deﬁnitive surgery or
radiotherapy permits aggressive clones driving the growth but
selecting out for other important pathways associated with meta-
static survival.
On the other hand, mutations from the androgen
receptor pathway are rare consistent with the data seen in breast
cancer.
Finally, Eric Small and the Stand Up to CancerWest Coast Dream
Team presented provocative data at the 2015 American Society
for Clinical Oncology meeting where they analysed 124 castrate
resistant prostate cancer biopsies, a third of which were adeno-
carcinoma, 13% of which were neuroendocrine differentiated, half
of which revealed changes consistent with a mixture of both his-
tologies. Indeed, ongoing analysis revealed a new type of prostate
cancer called intermediate atypical carcinoma, where the charac-
teristic cell changes have been described, but more importantly, the
genes that can discriminate clearly between adenocarcinoma, small
cell carcinoma and this new intermediate subtype have been
identiﬁed. Therefore it is felt that, like in many other tumour types,
ongoing molecular analysis of CRPC as it progresses is required
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